Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Expenses (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Accumulated Expenses over the past 15 years, most recently at $22.0 million for Q2 2025.

  • For Q2 2025, Accumulated Expenses fell 2.57% year-over-year to $22.0 million; the TTM value through May 2025 reached $22.0 million, down 2.57%, while the annual FY2025 figure was $22.0 million, 2.57% down from the prior year.
  • Accumulated Expenses for Q2 2025 was $22.0 million at Lifecore Biomedical, Inc. \De\, up from $19.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $22.5 million in Q2 2024 and troughed at $3.3 million in Q4 2021.
  • A 5-year average of $8.2 million and a median of $5.7 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: plummeted 53.64% in 2023 and later skyrocketed 443.74% in 2024.
  • Year by year, Accumulated Expenses stood at $3.3 million in 2021, then rose by 26.04% to $4.1 million in 2022, then fell by 18.27% to $3.4 million in 2023, then surged by 38.07% to $4.6 million in 2024, then soared by 374.15% to $22.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for LFCR at $22.0 million in Q2 2025, $19.7 million in Q1 2025, and $4.6 million in Q4 2024.